Holman also signed off on PMI's initial IQOS application in 2020. On March 18, Holman signed off on the third generation of PMI's heated, smokeless tobacco product, IQOS. It's unclear when Holman had recused himself, but it appears to have been less than four months ago. In a statement, an FDA spokesperson added that 'agency employees are free to pursue employment outside of the government and are required to immediately disclose that they are exploring opportunities outside the government.' Regulatory headaches Holman had 'recused himself, consistent with agency ethics policies, from all CTP/FDA work while exploring career opportunities outside of government,' King wrote. In a memo later Tuesday, CTP Director Brian King relayed the news of Holman's exit to staff and noted that he had been on leave for an unspecified amount of time. Holman, a biochemist by training, was at the FDA for over 20 years and director of the CTP's Office of Science since 2017. On Tuesday, Matt Holman, director of the Office of Science at the FDA's Center for Tobacco Products (CTP), announced his departure, effective immediately, to accept a position at PMI. Juul-largely blamed for an epidemic of youth vaping-is partly owned by Altria, which spun-off PMI in 2008. Earlier this month, for instance, the FDA announced an embarrassing backpedal in its bungled attempt to ban Juul e-cigarette products. It is the second high-profile FDA hire by PMI in recent months, and it comes at a time when the FDA is struggling to regulate the evolving smoking and vaping products by companies such as PMI.

The top tobacco scientist at the Food and Drug Administration has left his job to go work for tobacco giant Philip Morris International (PMI), best known as the maker of Marlboro cigarettes.

Kerbal space program free 02018